25.92
+7.28%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Veracyte
From its filings with the US Securities and Exchange Commission
Veracyte is based in South San Francisco, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker VCYT. The SEC classifies its business as medical laboratories. In the fiscal year to 31 December 2025, it reported revenue of $517.1m and net income of $66.4m. At that date it held total assets of $1.41bn and shareholders' equity of $1.31bn. By business, Testing revenue brought in 95.4% of revenue, followed by Product revenue at 2.8% and Biopharmaceutical and other revenue at 1.9%. By region, United States accounted for 96.0%, followed by International at 4.0%.
At Veracyte, we believe that exceptional cancer care begins with exceptional diagnostics. We are a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic and predictive treatment decisions. Insights from these tests help patients avoid unnecessary procedures and interventions and accelerate time to appropriate treatment, thereby improving outcomes for patients across our global markets.
Through our leading portfolio of comprehensive molecular diagnostic tests, we are focused on progressing patient care from the current standard to a more individualized approach, leveraging each patient’s unique cancer biology to improve their outcomes. We serve global markets with two complementary models. In the United States, we offer laboratory developed tests, or LDTs, through our centralized Clinical Laboratory Improvement Amendments of 1988, or CLIA, certified laboratories in South San Francisco and San Diego, California, supported by our cytopathology expertise in Austin, Texas. Outside of the United States, we provide in vitro diagnostic, or IVD, tests to patients through distribution to laboratories and hospitals that can perform the tests locally. In the United States, we currently offer tests in prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder).
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 30 Oct 2013
- Employees
- 755
- Website
- veracyte.com ↗
- Head office
- 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- Incorporated in
- DE
- Classification
- Services-Medical Laboratories
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Robert EpsteinIndependent Chairman of the Board$359,997
- Mr. Marc StapleyChief Executive Officer, Director, since 2021$6.8m
- Ms. Rebecca ChambersChief Financial Officer$3.6m
- Ms. Annie McguireChief Human Resources Officer, General Counsel$3.1m
- Dr. Phillip FebboChief Scientific Officer, Chief Medical Officer$2.8m
- Mr. John LeiteGlobal Chief Commercial Officer$3.1m
- Dr. Eliav BarrIndependent Director$304,997
- Ms. Muna BhanjiIndependent Director$309,997
- Ms. Karin EasthamIndependent Director$324,997
- Mr. Jens HolsteinIndependent Director$327,497
- Mr. Evan JonesIndependent Director$324,997
- Dr. Tom MillerIndependent Director$518,330
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 51
- Environment
- 6
- Social
- 99
- Governance
- 48
- Direct emissions (scope 1)
- 679 t
- Energy emissions (scope 2)
- 448 t
- Women in the workforce
- 55%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Veracyte Inc has a strong and experienced leadership team, which enables effective decision-making and strategic planning.
- The company has developed innovative and highly accurate genomic diagnostic tests that provide valuable insights for physicians and patients.
- Veracyte has established partnerships with key healthcare providers, allowing for broader market reach and increased adoption of its products.
Weaknesses
- Veracyte's success heavily relies on the acceptance and adoption of genomic testing technology within the medical community.
- The company faces potential challenges in terms of regulatory compliance and obtaining necessary approvals for its diagnostic tests.
- Veracyte may experience increased competition in the future as new players enter the genomic diagnostic testing market.
Opportunities
- The growing focus on personalized medicine and precision healthcare presents significant opportunities for Veracyte to expand its customer base and market share.
- The increasing prevalence of diseases such as cancer and lung disorders provides a substantial opportunity for Veracyte to further develop and market its diagnostic tests.
- Veracyte can leverage advancements in technology and data analysis to enhance the accuracy and efficiency of its genomic testing platform.
Threats
- Changes in healthcare policies and reimbursement regulations could impact the pricing and accessibility of Veracyte's diagnostic tests.
- Veracyte may face legal and ethical challenges regarding the collection, storage, and use of genetic data for diagnostic purposes.
- The emergence of alternative diagnostic technologies and approaches poses a threat to Veracyte's market position.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.